Mobile

Assessment of Metabolic and pathological Response to Treatment with Radio-chemotherapy (RCT) and Immunotherapy (ImT) before Surgery in locally advanced Esophageal and gastro-esophageal junction cancer...

Mise à jour : Il y a 4 ans
Référence : EUCTR2016-000935-42

Assessment of Metabolic and pathological Response to Treatment with Radio-chemotherapy (RCT) and Immunotherapy (ImT) before Surgery in locally advanced Esophageal and gastro-esophageal junction cancer: ARTemIS-Eso, a three-level, open-label, phase I-II study

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To establish the recommended schedule of immunotherapy (monalizumab) that can be safely administered in combination with RCT in patients with esophageal SCC or ADC including gastro-esophageal junction ADC.

Critère d'inclusion

  • Adenocarcinomas of the esophagus or gastro-esophageal junction and squamous cell carcinoma of the esophagus

Liens